Order
Careers
Contact Us
Investors
Sign in

Adaptive Biotechnologies

Order
Careers
Contact Us
Investors
Sign in

Immune Medicine Platform
Platform Overview The Adaptive Immune System Publications
Products & Services
LIFE SCIENCES RESEARCH
immunoSEQ
CLINICAL DIAGNOSTICS
clonoSEQ Pipeline
DRUG DISCOVERY
Cellular Therapy Neutralizing Antibodies Vaccines
PARTNERSHIPS
COVID-19 Partnerships Neutralizing Antibodies Cancer Cellular Therapy TCR-Antigen Map Biopharma Partnerships Strategic Collaborators
ABOUT US
Our Story Leadership Blog Culture Careers Investors Newsroom Contact Us Media Resources

CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence

Corporate/Research
(855) 466-8667
Diagnostics
(888) 552-8988

Immune Medicine Platform

Platform Overview
The Adaptive Immune System
Publications

Products & Services

LIFE SCIENCES RESEARCH
- immunoSEQ
CLINICAL DIAGNOSTICS
- clonoSEQ
- Pipeline
DRUG DISCOVERY

Partnerships

COVID-19 Partnerships
Neutralizing Antibodies
Cancer Cellular Therapy
TCR-Antigen Map
Biopharma Partnerships
Strategic Collaborators

About Us

Our Story
Leadership
Blog
Culture
Careers
Newsroom
Media Resources
Contact Us

© Adaptive Biotechnologies. All Rights Reserved.

Legal Notices
Privacy Policies
Terms of Use
Cookie Policy
Code of Conduct
Supplier Code of Conduct
Licenses
Do Not Sell My Info (CA Residents)

Chief Scientific Officer Harlan Robins on the Case for T-cells: Understanding Exposure and Immunity to COVID-19

Read More